URAPIDIL TEVA LP 60 mg, extended-release capsule 30 capsules
Active ingredients: Urapidil
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- URAPIDIL TEVA LP 60 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) de 30 gélule(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Aug 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62675549CIP73020278CIP133400930202784Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| URAPIDILgélule | 60 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.